Acute and long-term antiplatelet therapy
Clinical presentations of atherothrombotic vascular disease, i.e., acute coronary syndromes, cerebrovascular events and events associated with peripheral arterial disease, are the major causes of mortality and morbidity worldwide. Platelet activation and aggregation play an important role in the pro...
Gespeichert in:
| Veröffentlicht in: | Drugs of Today 2008-05, Vol.44 (5), p.331-352 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 352 |
|---|---|
| container_issue | 5 |
| container_start_page | 331 |
| container_title | Drugs of Today |
| container_volume | 44 |
| creator | Papathanasiou, Athanasios I Goudevenos, John A Mikhailidis, Dimitri P Tselepis, Alexandros D |
| description | Clinical presentations of atherothrombotic vascular disease, i.e., acute coronary syndromes, cerebrovascular events and events associated with peripheral arterial disease, are the major causes of mortality and morbidity worldwide. Platelet activation and aggregation play an important role in the progression and clinical presentation of atherothrombotic disease, and antiplatelet therapy improves outcome in patients with atherothrombotic vascular disease. Aspirin has been the cornerstone of antiplatelet therapy for many decades, but in recent years, adenosine diphosphate (ADP) receptor antagonists, mainly clopidogrel and ticlopidine, and glycoprotein (GP) IIb/IIIa (integrin alpha IIb beta 3) inhibitors have also shown similar effectiveness. This review briefly summarizes the major clinical trials and recommendations for the efficacy and safety of antiplatelet therapy in patients with established atherothrombotic disease. |
| doi_str_mv | 10.1358/dot.2008.44.5.1215717 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71663902</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71663902</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-ffa71bb65702f4ab34c9831d947586ce7371a4a8728fbaaee7bfe6dffc745b273</originalsourceid><addsrcrecordid>eNpF0MtKw0AUBuBZKLZWH0HpStwkzv2yLMUbFNzoepiZnNFK0sSZyaJvb4oBV4cD_38OfAjdEFwTJvRD05eaYqxrzmtRE0qEIuoMLYk0pmLGsAW6zPkbYyok5xdoQbTgmjC5RPebMBZYu0OzbvvDZ1UgddNW9kPrCrRQ1uULkhuOV-g8ujbD9TxX6OPp8X37Uu3enl-3m10VGFalitEp4r0UCtPInWc8GM1IY7gSWgZQTBHHnVZUR-8cgPIRZBNjUFx4qtgK3f3dHVL_M0IuttvnAG3rDtCP2SoiJTOYTkHxFwypzzlBtEPady4dLcH2xGInFntisZxbYWeWqXc7Pxh9B81_azZhv5ZaYK4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71663902</pqid></control><display><type>article</type><title>Acute and long-term antiplatelet therapy</title><source>MEDLINE</source><source>Portico (Triggered Content) Journals</source><creator>Papathanasiou, Athanasios I ; Goudevenos, John A ; Mikhailidis, Dimitri P ; Tselepis, Alexandros D</creator><creatorcontrib>Papathanasiou, Athanasios I ; Goudevenos, John A ; Mikhailidis, Dimitri P ; Tselepis, Alexandros D</creatorcontrib><description>Clinical presentations of atherothrombotic vascular disease, i.e., acute coronary syndromes, cerebrovascular events and events associated with peripheral arterial disease, are the major causes of mortality and morbidity worldwide. Platelet activation and aggregation play an important role in the progression and clinical presentation of atherothrombotic disease, and antiplatelet therapy improves outcome in patients with atherothrombotic vascular disease. Aspirin has been the cornerstone of antiplatelet therapy for many decades, but in recent years, adenosine diphosphate (ADP) receptor antagonists, mainly clopidogrel and ticlopidine, and glycoprotein (GP) IIb/IIIa (integrin alpha IIb beta 3) inhibitors have also shown similar effectiveness. This review briefly summarizes the major clinical trials and recommendations for the efficacy and safety of antiplatelet therapy in patients with established atherothrombotic disease.</description><identifier>ISSN: 1699-3993</identifier><identifier>ISSN: 1699-4019</identifier><identifier>DOI: 10.1358/dot.2008.44.5.1215717</identifier><identifier>PMID: 18548136</identifier><language>eng</language><publisher>Spain</publisher><subject>Acute Coronary Syndrome - drug therapy ; Aspirin - therapeutic use ; Humans ; Myocardial Infarction - drug therapy ; Peripheral Vascular Diseases - drug therapy ; Platelet Activation - drug effects ; Platelet Aggregation Inhibitors - therapeutic use ; Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors ; Purinergic P2 Receptor Antagonists ; Stroke - drug therapy</subject><ispartof>Drugs of Today, 2008-05, Vol.44 (5), p.331-352</ispartof><rights>Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c307t-ffa71bb65702f4ab34c9831d947586ce7371a4a8728fbaaee7bfe6dffc745b273</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18548136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Papathanasiou, Athanasios I</creatorcontrib><creatorcontrib>Goudevenos, John A</creatorcontrib><creatorcontrib>Mikhailidis, Dimitri P</creatorcontrib><creatorcontrib>Tselepis, Alexandros D</creatorcontrib><title>Acute and long-term antiplatelet therapy</title><title>Drugs of Today</title><addtitle>Drugs Today (Barc)</addtitle><description>Clinical presentations of atherothrombotic vascular disease, i.e., acute coronary syndromes, cerebrovascular events and events associated with peripheral arterial disease, are the major causes of mortality and morbidity worldwide. Platelet activation and aggregation play an important role in the progression and clinical presentation of atherothrombotic disease, and antiplatelet therapy improves outcome in patients with atherothrombotic vascular disease. Aspirin has been the cornerstone of antiplatelet therapy for many decades, but in recent years, adenosine diphosphate (ADP) receptor antagonists, mainly clopidogrel and ticlopidine, and glycoprotein (GP) IIb/IIIa (integrin alpha IIb beta 3) inhibitors have also shown similar effectiveness. This review briefly summarizes the major clinical trials and recommendations for the efficacy and safety of antiplatelet therapy in patients with established atherothrombotic disease.</description><subject>Acute Coronary Syndrome - drug therapy</subject><subject>Aspirin - therapeutic use</subject><subject>Humans</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Peripheral Vascular Diseases - drug therapy</subject><subject>Platelet Activation - drug effects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors</subject><subject>Purinergic P2 Receptor Antagonists</subject><subject>Stroke - drug therapy</subject><issn>1699-3993</issn><issn>1699-4019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0MtKw0AUBuBZKLZWH0HpStwkzv2yLMUbFNzoepiZnNFK0sSZyaJvb4oBV4cD_38OfAjdEFwTJvRD05eaYqxrzmtRE0qEIuoMLYk0pmLGsAW6zPkbYyok5xdoQbTgmjC5RPebMBZYu0OzbvvDZ1UgddNW9kPrCrRQ1uULkhuOV-g8ujbD9TxX6OPp8X37Uu3enl-3m10VGFalitEp4r0UCtPInWc8GM1IY7gSWgZQTBHHnVZUR-8cgPIRZBNjUFx4qtgK3f3dHVL_M0IuttvnAG3rDtCP2SoiJTOYTkHxFwypzzlBtEPady4dLcH2xGInFntisZxbYWeWqXc7Pxh9B81_azZhv5ZaYK4</recordid><startdate>20080501</startdate><enddate>20080501</enddate><creator>Papathanasiou, Athanasios I</creator><creator>Goudevenos, John A</creator><creator>Mikhailidis, Dimitri P</creator><creator>Tselepis, Alexandros D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080501</creationdate><title>Acute and long-term antiplatelet therapy</title><author>Papathanasiou, Athanasios I ; Goudevenos, John A ; Mikhailidis, Dimitri P ; Tselepis, Alexandros D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-ffa71bb65702f4ab34c9831d947586ce7371a4a8728fbaaee7bfe6dffc745b273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acute Coronary Syndrome - drug therapy</topic><topic>Aspirin - therapeutic use</topic><topic>Humans</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Peripheral Vascular Diseases - drug therapy</topic><topic>Platelet Activation - drug effects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors</topic><topic>Purinergic P2 Receptor Antagonists</topic><topic>Stroke - drug therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>Papathanasiou, Athanasios I</creatorcontrib><creatorcontrib>Goudevenos, John A</creatorcontrib><creatorcontrib>Mikhailidis, Dimitri P</creatorcontrib><creatorcontrib>Tselepis, Alexandros D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs of Today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Papathanasiou, Athanasios I</au><au>Goudevenos, John A</au><au>Mikhailidis, Dimitri P</au><au>Tselepis, Alexandros D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute and long-term antiplatelet therapy</atitle><jtitle>Drugs of Today</jtitle><addtitle>Drugs Today (Barc)</addtitle><date>2008-05-01</date><risdate>2008</risdate><volume>44</volume><issue>5</issue><spage>331</spage><epage>352</epage><pages>331-352</pages><issn>1699-3993</issn><issn>1699-4019</issn><abstract>Clinical presentations of atherothrombotic vascular disease, i.e., acute coronary syndromes, cerebrovascular events and events associated with peripheral arterial disease, are the major causes of mortality and morbidity worldwide. Platelet activation and aggregation play an important role in the progression and clinical presentation of atherothrombotic disease, and antiplatelet therapy improves outcome in patients with atherothrombotic vascular disease. Aspirin has been the cornerstone of antiplatelet therapy for many decades, but in recent years, adenosine diphosphate (ADP) receptor antagonists, mainly clopidogrel and ticlopidine, and glycoprotein (GP) IIb/IIIa (integrin alpha IIb beta 3) inhibitors have also shown similar effectiveness. This review briefly summarizes the major clinical trials and recommendations for the efficacy and safety of antiplatelet therapy in patients with established atherothrombotic disease.</abstract><cop>Spain</cop><pmid>18548136</pmid><doi>10.1358/dot.2008.44.5.1215717</doi><tpages>22</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1699-3993 |
| ispartof | Drugs of Today, 2008-05, Vol.44 (5), p.331-352 |
| issn | 1699-3993 1699-4019 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71663902 |
| source | MEDLINE; Portico (Triggered Content) Journals |
| subjects | Acute Coronary Syndrome - drug therapy Aspirin - therapeutic use Humans Myocardial Infarction - drug therapy Peripheral Vascular Diseases - drug therapy Platelet Activation - drug effects Platelet Aggregation Inhibitors - therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Purinergic P2 Receptor Antagonists Stroke - drug therapy |
| title | Acute and long-term antiplatelet therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T13%3A10%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20and%20long-term%20antiplatelet%20therapy&rft.jtitle=Drugs%20of%20Today&rft.au=Papathanasiou,%20Athanasios%20I&rft.date=2008-05-01&rft.volume=44&rft.issue=5&rft.spage=331&rft.epage=352&rft.pages=331-352&rft.issn=1699-3993&rft_id=info:doi/10.1358/dot.2008.44.5.1215717&rft_dat=%3Cproquest_cross%3E71663902%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71663902&rft_id=info:pmid/18548136&rfr_iscdi=true |